NO20060080L - Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer - Google Patents

Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer

Info

Publication number
NO20060080L
NO20060080L NO20060080A NO20060080A NO20060080L NO 20060080 L NO20060080 L NO 20060080L NO 20060080 A NO20060080 A NO 20060080A NO 20060080 A NO20060080 A NO 20060080A NO 20060080 L NO20060080 L NO 20060080L
Authority
NO
Norway
Prior art keywords
liver
dition
pyrrole
derivatives
receptor modulators
Prior art date
Application number
NO20060080A
Other languages
English (en)
Norwegian (no)
Inventor
Patrik Holm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060080L publication Critical patent/NO20060080L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20060080A 2003-07-11 2006-01-05 Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer NO20060080L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316237.7A GB0316237D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001115 WO2005005416A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
NO20060080L true NO20060080L (no) 2006-02-08

Family

ID=27741986

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060080A NO20060080L (no) 2003-07-11 2006-01-05 Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer

Country Status (26)

Country Link
US (1) US20060189663A1 (xx)
EP (1) EP1646625B1 (xx)
JP (1) JP2007521313A (xx)
KR (1) KR20060034284A (xx)
CN (1) CN100478340C (xx)
AR (1) AR045720A1 (xx)
AT (1) ATE399776T1 (xx)
AU (1) AU2004256000B2 (xx)
BR (1) BRPI0412479A (xx)
CA (1) CA2532068A1 (xx)
CO (1) CO5640134A2 (xx)
DE (1) DE602004014772D1 (xx)
ES (1) ES2308205T3 (xx)
GB (1) GB0316237D0 (xx)
HK (1) HK1088318A1 (xx)
IL (1) IL172759A0 (xx)
IS (1) IS8291A (xx)
MX (1) MXPA06000447A (xx)
NO (1) NO20060080L (xx)
RU (1) RU2006102129A (xx)
SA (1) SA04250203B1 (xx)
TW (1) TW200507836A (xx)
UA (1) UA82108C2 (xx)
UY (1) UY28407A1 (xx)
WO (1) WO2005005416A1 (xx)
ZA (1) ZA200600229B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
RU2007130152A (ru) 2005-01-10 2009-02-20 Астразенека Аб (Se) Производные 1, 1-диоксидов изотиазол-3(2h)-онов в качестве модуляторов печеночных х-рецепторов
EP1907564B1 (en) * 2005-06-28 2013-10-23 Daiichi Sankyo Company, Limited Lxr ligand testing method
AU2007286807B2 (en) 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
WO2008103818A1 (en) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Therapeutic cotinine compositions
PT2868315T (pt) * 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
BRPI0910175A2 (pt) 2008-07-01 2017-03-21 Genentech Inc composto de fórmula i e ii, composição farmacêutica, método de inibição do crescimento de células anormais ou de tratamento de um distúrbio hiperproliferativo em um mamífero e método de tratamento de uma doença inflamatória em um mamífero
KR101901741B1 (ko) 2010-09-07 2018-10-01 서울대학교산학협력단 세스터터핀 화합물 및 이들 물질의 용도
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
KR200492570Y1 (ko) 2018-12-04 2020-11-05 박규환 조립식 계단장치를 위한 발판
AU2020401286A1 (en) 2019-12-13 2022-06-23 Inspirna, Inc. Metal salts and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE284387T1 (de) * 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
EP1212065A4 (en) * 1999-07-08 2004-02-11 Tularik Inc COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL

Also Published As

Publication number Publication date
BRPI0412479A (pt) 2006-09-19
UA82108C2 (uk) 2008-03-11
CN100478340C (zh) 2009-04-15
WO2005005416A1 (en) 2005-01-20
AU2004256000B2 (en) 2007-07-26
UY28407A1 (es) 2005-02-28
RU2006102129A (ru) 2006-08-27
EP1646625A1 (en) 2006-04-19
IS8291A (is) 2006-02-09
CO5640134A2 (es) 2006-05-31
US20060189663A1 (en) 2006-08-24
AR045720A1 (es) 2005-11-09
EP1646625B1 (en) 2008-07-02
KR20060034284A (ko) 2006-04-21
TW200507836A (en) 2005-03-01
CA2532068A1 (en) 2005-01-20
GB0316237D0 (en) 2003-08-13
JP2007521313A (ja) 2007-08-02
SA04250203B1 (ar) 2008-02-25
DE602004014772D1 (de) 2008-08-14
CN1820003A (zh) 2006-08-16
ATE399776T1 (de) 2008-07-15
ZA200600229B (en) 2007-04-25
HK1088318A1 (en) 2006-11-03
MXPA06000447A (es) 2006-04-07
AU2004256000A1 (en) 2005-01-20
IL172759A0 (en) 2006-04-10
ES2308205T3 (es) 2008-12-01

Similar Documents

Publication Publication Date Title
NO20060080L (no) Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer
NO20060081L (no) Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
NO20073250L (no) Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
CN104302634B (zh) 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
NO20055892L (no) Karboksylsyrederivater
WO2007050726A3 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
CN104995176B (zh) 调节bace所介导的app加工的乙内酰脲
NO20073248L (no) Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
WO2009009501A3 (en) Non-basic melanin concentrating hormone receptor-1 antagonists and methods
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
CN103432070B (zh) 左乙拉西坦注射液和制法
CN108456168A (zh) 一类结构新颖的c19二萜生物碱及其用途
SE0500056D0 (sv) Therapeutic agents 4
SE0500058D0 (sv) Therapeutic agents 5
EP1435353A1 (en) Novel heterocyclic compound and anti-inflammatory agent
CN106459016A (zh) 1,1’‑(1,6‑二氧代‑1,6‑己二基)双‑d‑脯氨酸的前药
EP2412705B1 (en) Novel therapeutic agent for cognitive impairment
Ma et al. Straightforward and effective synthesis of γ-aminobutyric acid transporter subtype 2-selective acyl-substituted azaspiro [4.5] decanes
Sauerberg et al. Structure–activity relationships of dimeric PPAR agonists
CN104523712B (zh) 一种盐酸吡格列酮格列美脲片剂组合物
US5087628A (en) 4,4'-[9H-fluoren-9-ylidenebis (methylene)]bispyrimidine for treating neurological disorders
CN103788058B (zh) 一种木脂素类化合物及其在防治阿尔茨海默症中的应用
CA2664300A1 (en) Agent for preventing onset of post-stroke reflex sympathetic dystrophy
TW200600094A (en) Pharmaceutical compositions for prevention or treatment of disorders of lipid metabolism

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application